|
Market Closed -
Deutsche Boerse AG
10:17:12 2026-09-11 am EDT
|
5-day change | 1st Jan Change | ||
| 137.40 EUR | +0.18% |
|
-2.03% | -13.20% |
| Sep. 11 | AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal | MT |
| Sep. 11 | AstraZeneca's breast cancer pill fails in late-stage trial | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 245,576 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -14.68% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 265,026 | 257,343 | 248,828 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -14.83% | -2.9% | -3.31% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.3x | 17.7x | 15.3x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.55x | 4.04x | 3.44x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.2x | 1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.88x | 3.67x | 3.44x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.19x | 3.85x | 3.49x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12x | 10.6x | 9.29x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.6x | 11.1x | 9.73x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.1x | 19.7x | 16.9x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.56% | 5.08% | 5.91% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.339 | 3.561 | 3.66 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.11% | 2.25% | 2.31% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.782 | 8.932 | 10.32 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.9% | 39.9% | 35.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,300 | 66,898 | 71,335 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,158 | 24,298 | 26,772 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,072 | 23,269 | 25,560 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,026 | 13,767 | 15,794 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,450 | 11,766 | 3,252 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 158.33 | 158.33 | 158.33 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.77x | 11.54x | 23.41x | 0.62% | 994B | |
| 29.54x | - | - | 2.02% | 640B | |
| 32.92x | 7.63x | 15.78x | 2.67% | 454B | |
| 18.71x | 4.57x | 11.31x | 2.91% | 337B | |
| 19.41x | 5.08x | 12.59x | 3.21% | 261B | |
| 20.34x | 4.19x | 11.96x | 2.11% | 246B | |
| 23.87x | 6.3x | 11.23x | 2.67% | 204B | |
| 12.3x | 4.48x | 9.37x | 4.08% | 190B | |
| -43.47x | 6.35x | 24.81x | 2.29% | 178B | |
| Average | 16.16x | 6.27x | 15.06x | 2.51% | 389.42B | |
| Weighted average by Cap. | 23.19x | 7.72x | 17.10x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- ZEG Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
